Toxicodynamic models for the understanding of aminoglycoside nephrotoxicity
Implications: design of strategies to reduce AG nephrotoxicity
2. Nephroprotectants
rationale: reduction of binding to acidic phospholipids
(Kishore et al, 1990 & 1992)
0.5
0.4
0.3
0.2
0.1
0.0
0.1
0.2
0.3
0.4
0.5
GM concentration (mM)
BUFFER
LIPOSOMES
0
1.25
2.5
5
PAA equivalents
in vitro
in vivo
0
50
100
150
200
250
Drug accumulation
(as % of GM alone)
Phospholipiduria
(% of base line)
0
100
200
300
400
500
GM + PAA
GM
GM + PAA
GM
Previous slide
Next slide
Back to first slide
View graphic version